ArticleDiscover oncology2024

Efficacy and prognostic factors of anti-PD1 and nivolumab-ipilimumab therapy in advanced melanoma patients resistant to prior ICI treatment.

Caner Acar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.